Selexipag-d7

• Description :

  Selexipag-d7 is the deuterium labeled Selexipag. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor) [1][2].

• CAS Number :

  [1265295-21-3]

• UNSPSC :

  12352005

• Target :

  Isotope-Labeled Compounds; Prostaglandin Receptor

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  GPCR/G Protein; Others

• Field of Research :

  Cardiovascular Disease; Endocrinology

• Purity :

  98.44

• Solubility :

  10 mM in DMSO|DMSO : ≥ 50mg/mL

• Smiles :

  CS(NC(COCCCCN(C1=CN=C(C2=CC=CC=C2)C(C3=CC=CC=C3)=N1)C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O)(=O)=O

• Molecular Formula :

  C26H25D7N4O4S

• Molecular Weight :

  503.66

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Kuwano K, et al. 2-[4-[ (5,6-diphenylpyrazin-2-yl) (isopropyl) amino]butoxy]-N- (methylsulfonyl) acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther. 2007 Sep;322 (3) :1181-8.|[3]Mous DS, et al. Treatment of rat congenital diaphragmatic hernia with sildenafil and NS-304, selexipag's active compound, at the pseudoglandular stage improves lung vasculature. Am J Physiol Lung Cell Mol Physiol. 2018 May 10.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• Isoform :

  IP